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Malignant thymomas are rare epithelial neoplasms of the anterior superior mediastinum that are typically invasive
in nature and have a higher risk of relapse that may ultimately lead to death. Here we report a case of an advanced
malignant thymoma that was successfully treated with neoadjuvant chemotherapy followed by surgical resection
and subsequently with advanced and novel radiation therapy techniques. A 65-year-old male was diagnosed with a
stage IV malignant thymoma with multiple metastatic lesions involving the left peripheral lung and pericardium.
Initial neoadjuvant chemotherapy with a cisplatin-based regimen resulted in a partial response allowing the inoperable
tumor to become operable. Following surgical resection of the residual disease, the tumor recurred within a year. The
patient then underwent a course of targeted three-dimensional intensity modulated radiation therapy (IMRT) and
image-guided radiation therapy (IGRT). Five years after radiation therapy, the localized soft tissue thickening at
the left upper lung anterior pleural space had resolved. Seven years after radiation therapy the tumor mass had
completely resolved. No recurrences were seen and the patient is well even 8 years after IMRT/IGRT with a
favorable outcome. Chemotherapy with targeted three-dimensional IMRT/IGRT should be considered the primary
modality for the management of advanced malignant thymoma patients.
Keywords: Intensity modulated radiation therapy, Image-guided radiation therapy, Mediastinal mass, Neoadjuvant
chemotherapy, Surgical resection, Thymic neoplasmBackground
Thymomas are rare epithelial neoplasms arising from
the thymus gland and account for nearly all primary
malignancies of the anterior superior mediastinum [1-3].
The term thymoma describes neoplasms that show no
overt atypia of the epithelial component. The exact
cause of thymomas remains unknown. These are typic-
ally slow-growing tumors that manifest themselves by
local extension and when metastatic, the lesions are gen-
erally confined to the pleura, pericardium, or diaphragm
[4-6]. The incidence of thymomas is estimated to be 1.3
cases per million population in the United States [7,8].
In general, thymomas are indolent tumors with a
tendency toward local recurrence rather than metastasis.
Thymic carcinomas, however, are typically invasive, with
a higher risk of relapse and ultimately lead to death* Correspondence: kreddy_usa@yahoo.com
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article, unless otherwise stated.[9,10]. Thymic carcinomas are rare and have been
reported to account for only 0.06% of all thymic neo-
plasms [11]. Thymoma patients more often present with
metastatic disease, with a 5-year survival of 30 to 50%
[12]. The management of inoperable advanced malig-
nant thymoma is difficult. The optimal treatment of
malignant thymoma depends upon the stage and ex-
tent of disease and includes a combination of surgical
resection, chemotherapy, and radiotherapy. However,
no clinical data from large randomized trials is avail-
able to guide the treatment, given the rarity of advanced
malignant thymomas.
Various case series and small prospective trials have
shown the clinical effectiveness of chemotherapy with
multimodality regimens in the management of advanced
malignant thymomas. Multi-agent chemotherapy is used
neoadjuvantly to downstage the tumor rendering inoper-
able carcinoma operable or as palliative treatment to
extend the patients’ life and improve their quality of life.Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Figure 1 Targeted three-dimensional intensity modulated radiation
therapy and image-guided radiation therapy (IMRT/IGRT) plan
depicting the high dose areas of radiation treatment in the lung
pleura and chest wall of the thymoma patient. Color changes from
red to light yellow to greenish blue indicate the radiation dose from
highest (in the central area) to the lowest (in the peripheral area) while
adequately covering the pericardium and minimizing the radiation
effect on the heart.
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platin in combination with vincristine, doxorubicin and
etoposide have been shown to render inoperable invasive
thymomas operable tumors [13]. Many case series and
small studies have reported > 50% response rates with
cisplatin-based chemotherapy and this has now be-
come the standard of care for inoperable or metastatic
malignant thymomas.
In this report, we describe a challenging case of a
recurrent advanced malignant thymoma complicated by
the presence of metastatic lesions in the lung and peri-
cardium. Specifically, we present our experience in man-
aging recurrent advanced malignant thymomas using
multi-agent chemotherapy with cisplatin, adriamycin,
vincristine, and cytoxan followed by surgical resection,
intensity modulated radiation therapy (IMRT), and
image-guided radiation therapy (IGRT). IMRT is an
advanced mode of high-precision radiotherapy that uses
computer-controlled multiple small radiation beams of
varying intensities to deliver precise radiation doses to a
malignant tumor or specific areas within the tumor. By
incorporating three-dimensional computed tomography
(CT) imaging technology, IMRT allows the radiation dose
to conform more precisely to the three-dimensional
shape of the tumor while modulating the intensity of
the radiation beam and minimizing its dose to those
organs and tissues unaffected by the cancer. IGRT uses
a variety of two-dimensional, three-dimensional and
four-dimensional imaging techniques that improve the
precision and accuracy of the delivery of radiation dose
to the targeted tumor tissue while minimizing the dose
to the surrounding normal tissue during the course of
radiation therapy.
Case presentation
A 65-year old Hispanic male presented with complaints
of chest pain and heaviness prior to the diagnosis of his
disease. The patient had a history of tobacco use but had
stopped smoking 20 years earlier. The patient had been
otherwise healthy all of his life. Approximately 4 to
6 weeks prior to his diagnosis, he experienced an
episode of chest pain and some mild shortness of breath.
Initially, the patient underwent a routine chest X-ray
and CT scan diagnostic procedures. Subsequently, a
thorascopic biopsy was performed, and using H & E
staining, tissue histology was carried out to detect the
tumor development. In addition, the patient underwent a
mediastinoscopy, thoracoscopy, and fine-needle biopsy to
confirm the diagnosis of his disease.
The diagnostic evaluation revealed the presence of a
stage IV malignant thymoma with multiple metastatic
lesions involving the left peripheral lung and pericar-
dium. Despite the presence of metastatic disease, these
lesions are still oftentimes known to be amenable tosurgical resection following treatment with induction
chemotherapy. Therefore, to down- stage the tumor and
to improve the patient’s chance of increased surgical
resectability, neoadjuvant chemotherapy was initially
employed. Since platinum with an anthracycline-based
triplet or quartet regimen is currently the consensus
treatment for malignant thymoma [14-17], this was
chosen as the neoadjuvant chemotherapy in this
patient. More specifically, the patient was initially
administered five cycles of quartet regimen consisting
of cisplatin, adriamycin, vincristine, and cytoxan. Subse-
quently, the patient received four cycles of cisplatin,
adriamycin, and cytoxan followed by surgical resection
of his residual disease. Despite the treatment with
neoadjuvant chemotherapy and subsequent surgical
resection the patient experienced recurrent chest
disease within a year.
In attempt to salvage this patient, the patient under-
went a course of post-operative and post-chemotherapy
IMRT/IGRT-based three-dimensional radiation therapy
to a dose of 7,440 cGy to the left chest wall, mediasti-
num, and left pericardium (Figure 1). The patient was
monitored for safety and efficacy using CT scans and a
MUltiple Gated Acquisition (MUGA) scan prior to and
after his chemoradiation therapy.
Results
Initial findings from the thorascopic biopsy indicated
that the patient had multiple pleural-based masses with
an associated small left pleural effusion. Assessment of
tissue histology using H & E staining revealed a mixture
of plum epithelial cells with both vesicular nuclei and
distinct nucleoli and small lymphocytes indicating the
presence of malignant thymoma (Figure 2). Following
Figure 2 H & E stain shows the histology of the malignant
thymoma. This was evidenced by the presence of a mixture of
plump epithelial cells with both vesicular nuclei and distinct nucleoli
and small lymphocytes (magnification = 400X).
Figure 3 Time-lapse computer tomography (CT) imaging of the
chest of the patient with thymoma. (A) Initial CT scan of the chest
prior to targeted three-dimensional intensity modulated radiation
therapy and image-guided radiation therapy (IMRT/IGRT) demonstrated
a 3.7 x 3.0-cm anterior mediastinal mass. (B) The CT scan of the
chest 5 years after post-operative chemotherapy and targeted
three-dimensional IMRT/IGRT shows that the localized soft tissue
thickening at the left upper lung anterior pleural space has resolved.
(C) The CT scan of the chest 7 years after post-operative chemotherapy
and targeted three-dimensional IMRT/IGRT shows that there is a
moderate dependent pleural thickening at the left lung base.
There is complete left lung atelectasis, but the previously seen
pleural disease had resolved.
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was provisionally suspected of having lymphoma; however,
the needle biopsy assessment showed lymph with aggre-
gates that were negative for lymphoma. Subsequent
diagnostic studies confirmed the presence of a stage IV
malignant thymoma. Further assessment using a multi-slice
CT scan indicated that the patient had multiple metastatic
lesions involving his left peripheral lung and pericardium.
In addition, the chest CT imaging revealed several mass
structures with the largest size being 3.4 × 6.7 cm in the left
hemithorax. Furthermore, there were also multiple medias-
tinal masses specifically located in the anterior mediastinal
region with the largest mass size measuring 3.2 cm.
The initial five cycles of neoadjuvant chemotherapy
with cisplatin, adriamycin, vincristine, and cytoxan was
well tolerated by the patient. However, this induction
therapy only resulted in reduction in the size of the
tumor masses. However, a partial response was observed
after the subsequent chemotherapy with four cycles of
cisplatin, adriamycin, and cytoxan. The patient then
underwent surgical resection of his residual disease. Des-
pite treatment with chemotherapy and surgical resection,
the patient experienced recurrent chest disease within a
year. An attempt was then made to salvage the patient
and he was treated with radiation therapy.
A pre-radiation therapy chest CT imaging revealed
several mass structures with the largest size measuring
3.7 × 3.0 cm in the left hemithorax (Figure 3A). In
addition, there were also multiple mediastinal masses lo-
cated in the anterior mediastinal region with the largest
mass size measuring 3.2 cm. To control the disease, the
patient then underwent a course of post-operative and
post-chemotherapy definitive IMRT/IGRT-based three-
dimensional radiation therapy to a dose of 7,440 cGy to
the left chest wall, mediastinum, and left pericardium. Apost-therapy chest CT imaging showed the presence of
only small sub-centimeter right middle lobe pulmonary
nodules with no discrete soft tissue mass or malignancy.
Follow-up CT imaging of the chest 5 years after the
patient’s chemoradiation therapy, revealed that the local-
ized soft tissue thickening at the left upper lung anterior
pleural space had resolved (Figure 3B). Seven years post-
chemoradiation therapy, CT imaging of the chest also
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post-radiation changes and fibrosis (Figure 3C). The
patient's post-radiation MUGA scan of the heart showed
that the left ventricular ejection fraction was within the
expected normal value of 61% 8 years after definitive
three-dimensional IMRT/IGRT.
Discussion
Malignant thymomas are rare human neoplasms
accounting for less than 0.5% of all malignancies. Due to
their rarity, knowledge of the optimal treatment regard-
ing these tumors is based on case reports or small
retrospective series. Management of thymic carcinoma
depends upon the clinical stage of the disease. Currently,
surgical resection remains the mainstay of treatment
for localized thymic malignancies [18]. However, the
complete resection of the tumor is particularly import-
ant in the management of thymic carcinoma [19]. The
resectability for stages I, II, III and IV of thymic carcinoma
has been 100%, 43 to 100%, 0 to 85%, and 0 to 42%,
respectively [20]. A study by Kondo et al. [21] has shown
that the 5-year survival rate is 66.9%, 29.8%, and 19.4% for
completely resected, incompletely resected, and non-
surgery groups, respectively.
In general, extensive mediastinal or lung invasion or
metastasis is a frequent finding in most newly diagnosed
patients. Despite complete surgical resection, over 50%
of patients with advanced disease experience recurrence
[21]. Consequently, treatment with multiple modalities
such as repeat surgical resection, chemotherapy, and
radiotherapy has been attempted but without general
consensus on the optimal approach [22]. It is known
that most thymic tumors are chemo- and radio-sensitive
[23-25] and, thus, a multimodality treatment that inte-
grates surgical resection with chemo- and radiotherapy
has been advocated for advanced stages with the aim to
improve both local and distal control of the disease and
prolong survival [26-28]. In addition, preoperative
(induction or neoadjuvant) chemotherapy has been suc-
cessfully used to down-stage unresectable tumors for
surgical resection and to prevent local and systemic
recurrences [24,27,29-37].
The present patient was diagnosed as having an
advanced stage IV malignant thymoma with multiple
metastatic lesions involving the left peripheral lung and
pericardium. Therefore, induction chemotherapy was
employed, followed by surgery, and then post-operative
definitive targeted three-dimensional IMRT/IGRT in this
patient. Since cisplatin-based combination chemotherapy
is effective against thymic tumors [35,38,39], cisplatin
was used in combination with adriamycin, vincristine,
and cytoxan as induction chemotherapy to down-stage
the tumor and to improve the surgical resectability of
the patient’s unresectable tumor. This initial inductionchemotherapy was found to be effective in reducing the
sizes of the masses with an acceptable safety and patient
tolerability; however, residual tumor was still present.
Additional cycles of induction chemotherapy with cis-
platin, adriamycin, and cytoxan yielded a partial re-
sponse and the residual disease was managed with
surgical resection.
Little has been reported on the role of advanced
radiation therapy in the management of malignant
thymoma. Until recently, no literature has demonstrated
the superiority of one radiation therapy method over
another. Despite the sensitivity of thymoma to radiation,
the best use of radiotherapy remains controversial.
Moreover, there remains no consensus on whether or
not adjuvant radiation is of any benefit in completely
resected thymoma. However, in this case study, we have
demonstrated that by using targeted three-dimensional
IMRT/IGRT, we were able to address the patient’s
extensive recurrent disease and treat critical structures
that were involved by the disease. In addition, our
treatment approach spared the patient from any long-
term detrimental side effects, especially to his myocar-
dium and other critical organs.Conclusion
Multimodality therapy involving both neoadjuvant
and post-operative chemotherapy in conjunction with
three-dimensional well-targeted IMRT/IGRT appears to
increase the success rates of complete resection and
improve survival in patients with metastasized thymic
carcinoma. Neoadjuvant chemotherapy with cisplatin,
adriamycin, vincristine, and cytoxan resulted in a partial
response allowing the inoperable tumor to become oper-
able in this patient. Following surgical resection, targeted
three-dimensional IMRT/IGRT was well tolerated with-
out any cardiac toxicity. Targeted three-dimensional
IMRT/IGRT proved to be clinically effective resulting in
no serious adverse events and more importantly achiev-
ing a complete response of the tumor leading to long-
term tumor control and increased survival of the patient
with minimal compromise in his quality of life.Consent
A written informed consent was obtained from the
patient for publication of this case report and any
accompanying images. A copy of the written consent is
available for review.
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